Skip to main content

Table 1 Baseline demographics and disease characteristics in all randomized subjects

From: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

  MF-DPI 800 μg QD PM (n = 308) MF-DPI 400 μg BID (n = 308) Placebo (n = 295)
Mean age, y 65.3 65.0 65.0
Sex, n (%)    
   Women 95 (31) 102 (33) 92 (31)
   Men 213 (69) 206 (67) 203 (69)
Race, n (%)    
   White 271 (88) 264 (86) 252 (85)
   Non-white 37 (12) 44 (14) 43 (15)
Mean body mass index, kg/m2 26.7* 26.1* 27.1
Mean COPD duration, y 7.33* 7.31 7.26
Pulmonary function    
   Prebronchodilator FEV1, L 1.32 1.25 1.26
   Postbronchodilator FEV1, L 1.45 1.38 1.41
% FEV1 predicted    
   Prebronchodilator 43 42 42
   Postbronchodilator 47 46 47
   Reversibility (%) 4 4 5
COPD severity, n (%)    
   FEV1 50%–<80% predicted 97 (32) 88 (29) 81 (28)
   FEV1 30%–<50% predicted 142 (46) 136 (44) 127 (43)
   FEV1 < 30% predicted 60 (20) 67 (22) 67 (23)
   Missing§ 8 (3) 17 (6) 20 (7)
  1. BID = twice daily; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; MF-DPI = mometasone furoate administered via a dry powder inhaler.
  2. *n = 305
  3. n = 306
  4. Sum of % values may not be 100% due to rounding.
  5. §Screen failures or inadequate data (at least one valid measure of prebronchodilator or postbronchodilator FEV1, but not both, were available).